Alere filed suit against Abbott Laboratories, claiming the medical device maker failed to get US antitrust clearance for the $5.8 billion merger underway between the two, potentially scuttling the controversial deal.
Abbott failed to “promptly secure antitrust approvals and other regulatory requirements,” Alere said in a filing in Delaware Chancery Court. The suit was filed under seal late Thursday and details weredisclosed in a filing on Friday.
Abbott has tried to get out of the agreement, offering to pay $30 million to $50 million of Alere’s legal costs. That offer was immediately rejected by Alere’s board earlier this year.
Full Content: Chicago Business
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
EU Conducts First-Ever Raids on a Company Under Foreign Subsidies Regulation
Apr 23, 2024 by
CPI
FTC Moves to Ban Non-Compete Agreements, Aiming to Boost Labor Mobility
Apr 23, 2024 by
CPI
Federal Judge Nods at $418M Deal in Real Estate Antitrust Suit
Apr 23, 2024 by
CPI
Mexican Watchdog Probes Amazon and Mercado Libre Over Loyalty Bundles
Apr 23, 2024 by
CPI
Competition Commission of India to Probe AI Landscape for Competition
Apr 23, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI